NCT07204275

A Study to Evaluate Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)

A Phase 2b/3 Adaptive, Randomized, Active-controlled Study Evaluating the Efficacy, Safety, and Tolerability of Povetacicept Versus Calcineurin Inhibitor in the Treatment of Primary Membranous Nephropathy

• Status: Recruiting
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 176 (estimated)
• Sponsor: Vertex Pharmaceuticals Incorporated · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the efficacy, safety, and tolerability of povetacicept in participants with primary membranous nephropathy (pMN).

Conditions

• Primary Membranous Nephropathy

Interventions

Type	Name	Description
DRUG	Povetacicept	Solution for Subcutaneous Injection.
DRUG	Tacrolimus	Capsules for Oral Administration.

Timeline

• Start date: 2025-09-30
• Primary completion: 2028-12-29
• Completion: 2028-12-29
• First posted: 2025-10-02
• Last updated: 2026-03-30

Locations

73 sites across 10 countries: United States, Australia, Brazil, China, Germany, Hungary, Italy, South Korea, Spain, United Kingdom

Regulatory

• FDA-regulated drug study